How do you decide if a CRO advisory before a full-time hire is right for a Series A company when RevOps exists but no revenue leader in 2027?

The two paths compared

A CRO advisory and a full-time CRO hire solve different problems, and conflating them is the most common mistake a Series A board makes. The advisory is a diagnostic and playbook-building function: a senior revenue practitioner spends 10-20 hours a week auditing the pipeline, interviewing the founder and RevOps team, and designing a repeatable process — territory logic, a qualification framework, a forecast cadence — that the existing team can run. It does not come with headcount authority. The advisor cannot fire an underperforming rep, approve a non-standard discount, or sit in as the accountable executive on a board call about quota attainment. What it does provide is pattern recognition: someone who has seen the same 15-40 employee, $1M-$5M ARR company shape before and can tell founder-led sales from a genuinely broken motion.

A full-time CRO, by contrast, is an execution hire. They own quota, they manage reps day to day, they sign off on comp plans, and they are accountable to the board for the number, not just the diagnosis. That authority is exactly what a company needs once the GTM model is proven and the constraint has shifted from "we don't know what our sales process should be" to "we know what it should be and now need someone driving it daily." Hiring that executive before the motion is validated is a common and expensive failure mode: the company ends up paying full-time compensation for someone to run diagnostic work that didn't need permanent headcount, and if the motion turns out to need a pivot, unwinding a senior executive hire is far more disruptive and costly than simply not renewing an advisory engagement.

The decision genuinely turns on what's missing. If RevOps exists and is competent at running the CRM and generating reports but has no one telling it what strategy to operationalize, that's a strategy gap — an advisory closes it. If the strategy is already reasonably clear (the ICP is known, the pricing works, deals close consistently) but nobody is managing the humans doing the selling, that's an execution gap — only a full-time hire with people-management authority closes that. Most Series A companies without a revenue leader are actually facing the first problem, which is why advisory-first is the more common and lower-risk sequencing, but it is not automatic — a company whose founder is already burned out from carrying the sales bag, or that has already validated a motion and just needs someone to scale a growing team, may be better served skipping the advisory step entirely.

There is also a hybrid failure mode worth naming: hiring a full-time VP of Sales instead of either option, on the theory that it's "cheaper than a CRO." A VP of Sales without CRO-level strategic scope will often replicate whatever motion they ran at their last company regardless of fit, because nobody above them is testing that assumption against your specific market. The advisory-versus-full-time-CRO decision is really about who validates the model before someone is paid full-time to run it at scale.

How to decide between them

The clearest way to make this decision is to work through it as a sequence of yes/no questions rather than a single judgment call, because the individual pieces (motion maturity, founder bandwidth, RevOps capability, board expectations) each point in different directions and need to be weighed separately before the answer becomes obvious.

Read the tree left to right rather than jumping to the bottom. The first fork is the most important: if you cannot say with confidence that your sales motion is repeatable — meaning a rep hired today could follow a defined process and hit a reasonable ramp target — the company is not ready for a full-time executive hire regardless of budget, because there is nothing proven yet for that executive to scale. That is squarely an advisory situation. The second fork matters because RevOps sophistication varies wildly at Series A: some RevOps hires are one person doing manual CRM cleanup with no bandwidth for strategy work, and handing them a sophisticated playbook before fixing basic data hygiene and lead routing wastes the advisor's time. In that case, the right move is a short, cheap RevOps tooling and process fix before the advisory engagement even starts.

If the motion is already validated, the decision shifts to a management-capacity question. A founder who is still closing 20-40% of the pipeline personally, with no one else running structured deal reviews or coaching reps on call quality, has an execution gap, not a strategy gap — that argues for full-time. But if the founder has already stepped back from day-to-day selling and the real question is "should we invest further in the current motion or invalidate parts of it before scaling," that is still advisory territory, because you are still testing assumptions, not managing headcount.

One caution about using this framework: don't let board pressure to "just hire someone" short-circuit the diagnostic step. A board that wants a CRO title on the org chart is optimizing for optics, not for reducing the actual risk in the business. The company that gets this decide wrong most often is the one that hires full-time to satisfy investor expectations of what a "real" post-Series-A company looks like, before the underlying revenue engine can support that level of fixed cost and executive authority.

Concrete numbers behind each option

The cost and structure differences between the two paths are large enough that they should be part of the decision, not an afterthought once the "right" choice is picked on pure fit. A CRO advisory engagement at this stage typically runs $5,000-$15,000 per month for 10-20 hours of weekly involvement, usually structured as a 6-12 month engagement with a 30/60/90-day diagnostic-to-playbook arc built in. A full-time CRO hire, by comparison, typically commands $200,000-$350,000 in total compensation (base plus bonus/OTE, before equity), which is a five-to-ten-times step up in fixed monthly cost and comes with the additional overhead of benefits, onboarding, and the organizational disruption of adding a senior executive who will want authority over comp plans, hiring, and process that currently sits with the founder or RevOps.

The revenue and team-size thresholds worth anchoring on: companies below roughly $2M ARR or with fewer than three sales reps generally do not have enough sales-management surface area to justify a full-time executive — the founder can still reasonably be the primary closer while an advisor builds the playbook around them. Above that, once a company is hiring its fourth rep or crossing $2M ARR with the founder spending less than 20% of their time on sales, the case for full-time strengthens considerably, because daily pipeline reviews, rep coaching, and deal escalation genuinely require more hours than a 10-20 hour weekly advisory can provide.

Deal-level numbers matter too, because they tell you how much revenue risk is riding on getting this decide right. Series A companies in this situation typically see $10,000-$30,000 annual contract values for SMB-focused products and $50,000-$150,000 ACV for mid-market plays, with sales cycles running 60-120 days. Forecast accuracy without a revenue leader tends to sit at 20-40%, versus 60-70% once a mature process and either a strong advisor-built playbook or a full-time CRO's discipline is in place — that forecast-accuracy gap is one of the most concrete, board-legible signals for whether the current setup (RevOps alone) is actually working. Win-rate data is similarly diagnostic: if 30-50% of closed-lost deals are "no decision" rather than competitive losses, that points to a qualification and process problem an advisory can fix quickly, not a headcount problem a full-time hire would solve any faster.

Budget-approval dynamics on the buying side also shape how urgently the company needs one option or the other. Series A buying committees are lean — typically 2-4 people, with discretionary spend authority often capped around $20,000-$30,000 before finance sign-off is required. A company without anyone able to consistently articulate the buyer's decision criteria will see inconsistent win rates regardless of which revenue-leadership structure it chooses, which is itself evidence that the more urgent fix might be a fast, cheap advisory diagnostic rather than a multi-month full-time search.

Implementation details and sequencing

Once the decide leans toward advisory, the sequencing matters as much as the choice itself, because a poorly run advisory engagement can waste the exact window a company has to figure out its motion before the next round. The first 30 days should be purely diagnostic: reviewing 12 months of deal history, interviewing the founder, RevOps lead, and any existing reps, and identifying no more than three specific bottlenecks — commonly lead response time, deal qualification, or pricing inconsistency. Trying to fix everything simultaneously in month one is the most common way advisory engagements stall.

Days 30-60 shift from diagnosis to playbook: defining the ideal customer profile with real criteria (not "companies like our best customer" but specific firmographic and behavioral filters), building a basic territory or segment model, and instituting a weekly forecast meeting with a simple three-stage pipeline review. This is also when the advisor should hand RevOps enough structure to operationalize — a lead-scoring model RevOps can build in the CRM, a commission structure RevOps can track, a pipeline stage definition RevOps can report against. If RevOps can't execute against a clearly defined playbook by day 60, that is itself a signal the company has a RevOps capability gap that needs its own fix, separate from the CRO question.

Days 60-90 are about coaching and proving the playbook survives without the advisor's constant presence: the advisor listens to founder sales calls and gives direct feedback, RevOps builds a lightweight dashboard covering pipeline velocity and win rate by source, and the team runs at least a few weeks with the advisor stepping back to see what breaks. The operating cadence during the full engagement should stay light — a weekly strategy call, a monthly deeper pipeline review, and ad hoc support for deal escalations — because an advisory that requires daily involvement has effectively become an unpaid full-time role and should be renegotiated as one.

The conversion decision itself should be triggered by evidence, not a calendar date. The clearest combined signal is forecast accuracy holding above roughly 60% for two consecutive quarters alongside first-hire rep productivity — new reps hitting around 80% of quota within six months — because together those indicate the motion is not just theoretically repeatable but has already been repeated by someone other than the founder. A company that hits neither signal by month six should extend the advisory rather than convert, since hiring a full-time CRO onto an unproven motion typically causes a six-to-twelve-month setback when the new executive inherits assumptions that don't hold and has to re-diagnose from scratch — the exact work the advisory was supposed to have already done.

Related questions

How is a fractional CRO different from a full-time CRO advisory retainer?

"Fractional" and "advisory" are often used interchangeably at this stage — both describe a part-time, non-headcount engagement, typically 10-20 hours a week, focused on strategy and coaching rather than direct people management or contract authority.

Can the same person do the advisory and later convert to the full-time role?

Yes, and it is common — the advisor already has 90 days of diagnostic context, so converting them removes ramp time a new external full-time hire would otherwise need, provided the board is comfortable with the transition.

Does a CRO advisory replace the need for a VP of Sales hire?

No — advisory provides strategy and coaching, not day-to-day rep management; once a company has 3+ reps, someone needs to own daily pipeline management, whether that's a VP of Sales, a full-time CRO, or the advisor's protégé within RevOps.

What if the board wants a CRO title immediately for investor optics?

Push back with the diagnostic data — a forecast accuracy or win-rate number showing the motion is unproven is a stronger argument against a premature full-time hire than a general preference for caution.

How does this decision change at Series B versus Series A?

At Series B, the motion is usually already validated and the team is larger, so the calculus shifts toward full-time by default; advisory at that stage is more often used for a specific gap (e.g., international expansion) rather than foundational GTM design.

FAQ

How do I know if my RevOps team is ready to support a CRO advisory versus needing to be upgraded first? RevOps is ready if they can produce a clean pipeline-by-stage and win-rate-by-source report within 24 hours without founder help. If they spend most of their time on manual data entry and can't name specific pipeline leaks unprompted, fix RevOps fundamentals before starting the advisory, or the engagement will burn its early weeks on data hygiene instead of strategy.

What happens if the CRO advisory recommends a GTM model that conflicts with the founder's vision? The advisor's job is to test the founder's thesis with data, not overrule it. A disagreement — say, the founder wants enterprise and the advisor sees only SMB traction — should be resolved with a small, time-boxed pilot (a handful of enterprise prospects over 90 days) rather than either side simply asserting they're right, with the outcome documented for the board.

What is the minimum revenue or team size where a full-time CRO becomes mandatory instead of advisory? Roughly five or more sales reps generating $2M+ in ARR, combined with the founder spending under 20% of their time on sales, is the point where daily management needs outstrip what a 10-20 hour weekly advisory can provide. Below that, advisory is typically sufficient.

How do I evaluate an advisory candidate differently from a full-time CRO candidate? For advisory, test diagnostic and teaching ability — have them audit your CRM live and name three specific leaks. For full-time, test execution and management track record — ask for references from a company where they scaled a team from a handful of reps to ten or more. A full-time candidate whose experience is entirely at later-stage companies often over-engineers process a Series A company can't sustain.

Is it a bad sign if RevOps pushes back on the advisory's recommendations? Not necessarily — thoughtful pushback grounded in data (e.g., "our CRM can't support that territory model without a rebuild") is useful friction. Reflexive pushback with no data behind it is more often a sign RevOps is protecting existing habits, which the advisor and founder should address directly rather than avoid.

Should the advisory engagement have a hard end date, or run indefinitely? It should have a defined initial term, typically 6-12 months, with renewal contingent on hitting specific diagnostic milestones. An open-ended advisory with no conversion criteria tends to drift into a permanent, under-authorized substitute for the full-time hire the company actually needs.

Sources

• https://hbr.org/topic/subject/sales
• https://www.forrester.com
• https://www.saastr.com
• https://www.bain.com/insights/topics/growth-strategy/
• https://www.mckinsey.com/capabilities/growth-marketing-and-sales
• https://www.gartner.com/en/sales
• https://www.forbes.com/sites/forbesbusinesscouncil/

Related on PULSE

• How to structure a fractional CRO engagement's first 90 days
• Signs your RevOps team needs a tooling reset before adding strategy
• What forecast accuracy benchmarks look like by company stage
• Comp plan design for the first three sales hires at Series A
• When to hire a VP of Sales instead of a CRO